Acrivon Therapeutics Q3 net loss narrows to $17.9 million
ACRV•Acrivon Therapeutics’ third-quarter 2026 net loss narrowed year over year to $17.9 million. The company reported $77.8 million in cash, cash equivalents and investments at September 30, with operating funding expected into fourth-quarter 2027.
1. Quarterly results and pipeline
Acrivon Therapeutics’ third-quarter net loss narrowed year over year to $17.9 million. Research and development expenses rose 7% to $14.5 million, while general and administrative expenses fell 33% to $4 million. The company said its acquisition of Phase 2-ready JAK1 inhibitor ACR-525 expands its pipeline into immunology and inflammation, initially targeting eosinophilic esophagitis. A prespecified interim analysis of ACR-368’s Phase 2b trial in all-comer serous endometrial cancer remains expected in fourth-quarter 2026.




